- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Zentalis Pharmaceuticals Llc is a biotechnology business based in the US. Zentalis Pharmaceuticals Llc shares (ZNTL) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.00 – a decrease of 2.91% over the previous week. Zentalis Pharmaceuticals Llc employs 124 staff and has a trailing 12-month revenue of around $40.6 million.
What's in this guide?
Our top picks for where to buy Zentalis Pharmaceuticals Llc stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Zentalis Pharmaceuticals Llc stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ZNTL. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Zentalis Pharmaceuticals Llc stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Zentalis Pharmaceuticals Llc stock price (NASDAQ: ZNTL)
Use our graph to track the performance of ZNTL stocks over time.Zentalis Pharmaceuticals Llc shares at a glance
Information last updated 2024-12-19.
| Latest market close | $3.00 |
|---|---|
| 52-week range | $2.66 - $18.07 |
| 50-day moving average | $3.31 |
| 200-day moving average | $6.89 |
| Wall St. target price | $9.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.50 |
Is it a good time to buy Zentalis Pharmaceuticals Llc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Zentalis Pharmaceuticals Llc price performance over time
Historical closes compared with the close of $3 from 2024-12-20
| 1 week (2024-12-13) | -2.91% |
|---|---|
| 1 month (2024-11-22) | -7.12% |
| 3 months (2024-09-20) | -28.91% |
| 6 months (2024-06-21) | -36.84% |
| 1 year (2023-12-22) | -79.18% |
|---|---|
| 2 years (2022-12-22) | -84.10% |
| 3 years (2021-12-22) | 82.01 |
| 5 years (2019-12-18) | N/A |
Zentalis Pharmaceuticals Llc financials
| Revenue TTM | $40.6 million |
|---|---|
| Gross profit TTM | $0 |
| Return on assets TTM | -25.24% |
| Return on equity TTM | -42.89% |
| Profit margin | 0% |
| Book value | $4.98 |
| Market Capitalization | $207.7 million |
TTM: trailing 12 months
Zentalis Pharmaceuticals Llc share dividends
We're not expecting Zentalis Pharmaceuticals Llc to pay a dividend over the next 12 months.
Zentalis Pharmaceuticals Llc share price volatility
Over the last 12 months, Zentalis Pharmaceuticals Llc's shares have ranged in value from as little as $2.66 up to $18.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Zentalis Pharmaceuticals Llc's is 1.742. This would suggest that Zentalis Pharmaceuticals Llc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Zentalis Pharmaceuticals Llc overview
Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc. ; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc.
Frequently asked questions
What percentage of Zentalis Pharmaceuticals Llc is owned by insiders or institutions?Currently 9.445% of Zentalis Pharmaceuticals Llc shares are held by insiders and 98.014% by institutions. How many people work for Zentalis Pharmaceuticals Llc?
Latest data suggests 124 work at Zentalis Pharmaceuticals Llc. When does the fiscal year end for Zentalis Pharmaceuticals Llc?
Zentalis Pharmaceuticals Llc's fiscal year ends in December. Where is Zentalis Pharmaceuticals Llc based?
Zentalis Pharmaceuticals Llc's address is: 1359 Broadway, New York, NY, United States, 10018 What is Zentalis Pharmaceuticals Llc's ISIN number?
Zentalis Pharmaceuticals Llc's international securities identification number is: US98943L1070 What is Zentalis Pharmaceuticals Llc's CUSIP number?
Zentalis Pharmaceuticals Llc's Committee on Uniform Securities Identification Procedures number is: 98943L107
More resources on Finder
More guides on Finder
-
Best Paper Trading Apps to Practice Trading With Fake Money in 2024
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
5 Best International Stock Brokers to Invest in Foreign Assets
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
-
9 Best Discount Brokers of 2024 for Low-Cost Trading
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Ask a question